Clinical Trial to Evaluate the Efficacy and Safety of CKD-342

Exclusion Criteria

• •1. Asthma
• •2. Previous medical history at screening (Nasal polyps within the previous two months, biopsies, ulcers, trauma, surgery, atrophic rhinitis, patients with a history of drug rhinitis)
• •3. Patients with untreated localized infection in nasal mucosa
• •4. Patients following administration of a combination of prohibited drugs in patients administered concomitant medications or trial period is expected to be inevitable
• •5. Patients with abnormal following laboratory test results at screening
• •* AST, ALT\>2times the upper limit of normal at screening
• •* Serum creatinine \>1.5times the upper limit of normal at screening
• •6. Previous history of acute or severe chronic sinusitis within 30 days at screening
• •7. The continue use of drugs that may affect the efficacy of the Investigational product
• •8. Start the immunotherapy or a change of doge within 1 month, at screening
• •9. If you have glaucoma or cataracts, herpes simplex, or around the eyes
• •10. Chronic obstructive pulmonary disease (COPD)
• •11. history of hypersensitivity reactions and for treaties or major components of the IP
• •12. Pregnant women, breast feeding women or women of childbearing potential must agree to use appropriate contraception methods
• •13. Alcohol or illegal drug abuse or dependence in patients
• •14. participation in any investigational or maketed drug within 4weeks preceding the screening visit
• •15. Patients that can not be participating in a clinical trial by investigator's discretion